Teva Pay-For-Delay Plausible; Judge Finds Payments Exceed Litigation Costs
This article was originally published in The Pink Sheet Daily
Executive Summary
Focused on $300 million in payments Cephalon made to generic firms to settle Provigil patent suits, case is second to proceed to trial since Supreme Court’s Actavis decision.